Skip to main content

Schizophrenia & Psychotic Disorders

Use of a transdermal patch to administer the second-generation anti-psychotic blonanserin improves both positive and negative symptoms of acute schizophrenia with manageable adverse effects, a new industry study shows.
Increased striatal activation in response to unexpected positive feedback may represent a neurological brain marker for psychosis risk, suggests a study published online in Neuropsychopharmacology.
Taking psychiatric medication did not hamper weight loss in people who participated in a structured weight loss program, researchers recently reported online in the journal Obesity.
Long-acting injectable (LAI) antipsychotics are superior to oral antipsychotics for preventing rehospitalization in older adults with schizophrenia, researchers report in The American Journal of Geriatric Psychiatry.
Refugees are at significantly increased risk of developing schizophrenia and other nonaffective psychoses, compared with nonrefugee migrants and native populations, according to a study published online in JAMA Psychiatry.

Leslie Citrome, MD, MPH, discusses the link between schizophrenia and diabetes, the role of metabolic syndrome, weight gain from antipsychotics, and interventions for patients with schizophrenia…

What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications? 
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top